Cognitive Impairment in Folate-Deficient Rats Corresponds to Depleted Brain Phosphatidylcholine and Is Prevented by Dietary Methionine without Lowering Plasma Homocysteine

Aron M. Troen,* Wei-Hsun Chao, Natalia A. Crivello, Kristen E. D’Anci, Barbara Shukitt-Hale, Don E. Smith, Jacob Selhub, and Irwin H. Rosenberg

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111

Abstract

Poor folate status is associated with cognitive decline and dementia in older adults. Although impaired brain methylation activity and homocysteine toxicity are widely thought to account for this association, how folate deficiency impairs cognition is uncertain. To better define the role of folate deficiency in cognitive dysfunction, we fed rats folate-deficient diets (0 mg FA/kg diet) with or without supplemental L-methionine for 10 wk, followed by cognitive testing and tissue collection for hematological and biochemical analysis. Folate deficiency with normal methionine impaired spatial memory and learning; however, this impairment was prevented when the folate-deficient diet was supplemented with methionine. Under conditions of folate deficiency, brain membrane content of the methylated phospholipid phosphatidylcholine was significantly depleted, which was reversed with supplemental methionine. In contrast, neither elevated plasma homocysteine nor brain S-adenosylmethionine and S-adenosylhomocysteine concentrations predicted cognitive impairment and its prevention by methionine. The correspondence of cognitive outcomes to changes in brain membrane phosphatidylcholine content suggests that altered phosphatidylcholine and possibly choline metabolism might contribute to the manifestation of folate deficiency-related cognitive dysfunction. J. Nutr. 138: 2502–2509, 2008.

Introduction

Poor folate status is increasingly recognized as an important and potentially modifiable risk factor for age-related cognitive decline and impairment in the elderly (1). Low circulating folate is significantly associated with mild cognitive impairment and depression in non-demented populations (2,3), it predicts increased risk of cognitive decline in longitudinal studies (4), and it is more frequently found in demented and impaired subjects than in unimpaired controls (5–8).

Poor folate status affects an estimated 5–10% of middle-aged and elderly adults in populations exposed to food folate fortification and its prevalence may be higher than 30% in unfortified populations (9). Folate status remains an important predictor of cognitive impairment and depression among elderly adults, even in populations exposed to food folate fortification (10,11). Its importance for cognition in the elderly is highlighted by a recent placebo-controlled, randomized clinical trial, which found that 3 y of folic acid (FA)3 supplementation delayed memory loss in elderly adults who had mildly elevated plasma total homocysteine (tHcy) and normal cognition at baseline (12). However, the relation of folate to cognition may depend on other nutritional factors, including vitamin B-12 (13,14).

The brain's high requirement for methylation activity is thought to underpin the apparent sensitivity of cognitive function to folate status (15,16). Folate serves as a carrier of 1-carbon groups for the methylation cycle (Fig. 1). In this cycle, the methyl group of methionine is activated by adenosine triphosphate to form S-adenosylmethionine (commonly abbreviated as SAM or AdoMet). SAM is the universal methyl donor in a multitude of methyl-transfer reactions including many that are of vital im-

1 Supported by the USDA, Agricultural Research Service, under agreement No. 58-1950-7-707. K. E. D. was supported by the NIH Training grant T32 DK007651. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA.


* To whom correspondence should be addressed. E-mail: aron.troen@tufts.edu.

3 Abbreviations used: BHMT, betaine-homocysteine methyltransferase; C, control diet; CDP-Choline, cytidine (5’)-diphosphocholine; FA, folic acid; FD, folate-deficient diet; FDM, folate-deficient, methionine-supplemented diet; PC-PE, phosphatidylcholine:phosphatidylethanolamine ratio; PEMT, phosphatidylethanolamine N-methyltransferase; Pi, inorganic phosphorous; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; tHcy, plasma total homocysteine.
importance to central nervous function, such as the synthesis of the key cell membrane component phosphatidylcholine from phosphatidylethanolamine. Through the transfer of its methyl-group, SAM is converted to S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine. Homocysteine can regenerate methionine for an additional methylation cycle by acquiring a new methyl group from 5-methyltetrahydrofolate in a reaction that is catalyzed in all tissues by methionine synthase (17). Alternatively, in liver and kidney, choline can provide lable methyl groups for the regeneration of methionine from homocysteine by betaine-homocysteine methyltransferase (BHMT). This alternative pathway is an important means of maintaining methylation capacity under conditions of folate, vitamin B-12, and methionine deficiency (18). Excess intracellular homocysteine can also be removed from the methylation pathway by conversion to cystathionine in the transsulfuration pathway or through export into circulation (17).

From these pathways, folate deficiency can generally be predicted to limit methionine synthesis and thereby SAM availability and to cause SAH to accumulate in tissues and homocysteine to accumulate in blood (hyperhomocysteinemia). At high concentrations, homocysteine might be directly toxic to cerebral blood vessels, but it is unclear whether mild elevations are similarly harmful. At the same time, rate-limiting concentrations of SAM together with feedback inhibition of some methyltransferase enzymes by elevated SAH concentrations would be expected to deplete the methylated products of such reactions. Nevertheless, these predictions do not always hold true, as the specific manifestations of folate deficiency differ by tissue (i.e. liver vs. brain), severity, and duration of the deficiency (19,20) and they can be modified by other metabolic factors, such as the availability of methionine and choline (21).

This complexity confounds the simple interpretation of epidemiological associations between cognitive impairments with folate, homocysteine, and other closely related metabolites and has impeded progress in clarifying the mechanisms that actually account for the epidemiological associations, whatever their theoretical plausibility (4,22,23).

Recent studies that have combined folate deficiency with other metabolic perturbations to expose genetic and pharmacological models of neurodegenerative disease to hyperhomocysteinemia have found that such treatments can exacerbate neurodegenerative or cognitive outcomes in models with preexisting neurological insults (24–26). However, such studies do not tell us whether the exacerbation of brain dysfunction is due to folate deficiency, hyperhomocysteinemia, or other factors (4,27). Earlier studies that specifically examined the effect of folate deficiency in rodents showed inconsistent effects on methylated derivatives of biogenic amine and cholinergic neurotransmitters (28–31). Other findings in folate-deficient rodents include ultrastructural abnormalities in rat brain capillaries (32) and slowed neurogenesis in mouse brain (33). Although folate-dependent changes in all these outcomes could ultimately lead to cognitive dysfunction, none of these studies report on the association of the neurochemical or structural impairments with cognitive outcomes.

In this study, we examined cognitive function in rats fed folate-deficient diets with and without supplemental methionine and determined the extent to which cognition in these rats corresponded to diet-induced changes in indicators of methylation activity: circulating homocysteine, liver and brain SAM and SAH, and brain membrane phosphatidylcholine and phosphatidylethanolamine.

Methods

Rats and diets. All animal procedures were approved by the Tufts-New England Medical Center and Jean Mayer USDA Human Nutrition Research Center on Aging Institutional Animal Care and Use Committee. Young male Sprague Dawley rats were systematically assigned to groups of similar mean body weight (~85 g), housed individually, and fed their assigned diet for 10 wk. Diets formulated with AIN 93M vitamin-free, ethanol-precipitated, casein-based basal mix (TD 03595, Harlan Teklad) and an appropriate vitamin mix to distinguish between methionine (17). Alternatively, in liver and kidney, choline can provide lable methyl groups for the regeneration of methionine from homocysteine by betaine-homocysteine methyltransferase (BHMT). This alternative pathway is an important means of maintaining methylation capacity under conditions of folate, vitamin B-12, and methionine deficiency (18). Excess intracellular homocysteine can also be removed from the methylation pathway by conversion to cystathionine in the transsulfuration pathway or through export into circulation (17).

From these pathways, folate deficiency can generally be predicted to limit methionine synthesis and thereby SAM availability and to cause SAH to accumulate in tissues and homocysteine to accumulate in blood (hyperhomocysteinemia). At high concentrations, homocysteine might be directly toxic to cerebral blood vessels, but it is unclear whether mild elevations are similarly harmful. At the same time, rate-limiting concentrations of SAM together with feedback inhibition of some methyltransferase enzymes by elevated SAH concentrations would be expected to deplete the methylated products of such reactions. Nevertheless, these predictions do not always hold true, as the specific manifestations of folate deficiency differ by tissue (i.e. liver vs. brain), severity, and duration of the deficiency (19,20) and they can be modified by other metabolic factors, such as the availability of methionine and choline (21).

This complexity confounds the simple interpretation of epidemiological associations between cognitive impairments with folate, homocysteine, and other closely related metabolites and has impeded progress in clarifying the mechanisms that actually account for the epidemiological associations, whatever their theoretical plausibility (4,22,23).

Recent studies that have combined folate deficiency with other metabolic perturbations to expose genetic and pharmacological models of neurodegenerative disease to hyperhomocysteinemia have found that such treatments can exacerbate neurodegenerative or cognitive outcomes in models with preexisting neurological insults (24–26). However, such studies do not tell us whether the exacerbation of brain dysfunction is due to folate deficiency, hyperhomocysteinemia, or other factors (4,27). Earlier studies that specifically examined the effect of folate deficiency in rodents showed inconsistent effects on methylated derivatives of biogenic amine and cholinergic neurotransmitters (28–31). Other findings in folate-deficient rodents include ultrastructural abnormalities in rat brain capillaries (32) and slowed neurogenesis in mouse brain (33). Although folate-dependent changes in all these outcomes could ultimately lead to cognitive dysfunction, none of these studies report on the association of the neurochemical or structural impairments with cognitive outcomes.

In this study, we examined cognitive function in rats fed folate-deficient diets with and without supplemental methionine and determined the extent to which cognition in these rats corresponded to diet-induced changes in indicators of methylation activity: circulating homocysteine, liver and brain SAM and SAH, and brain membrane phosphatidylcholine and phosphatidylethanolamine.

Methods

Rats and diets. All animal procedures were approved by the Tufts-New England Medical Center and Jean Mayer USDA Human Nutrition Research Center on Aging Institutional Animal Care and Use Committee. Young male Sprague Dawley rats were systematically assigned to groups of similar mean body weight (~85 g), housed individually, and fed their assigned diet for 10 wk. Diets formulated with AIN 93M vitamin-free, ethanol-precipitated, casein-based basal mix (TD 03595, Harlan Teklad) and an appropriate vitamin mix to distinguish between methionine and methionine deficiency (18). Alternatively, in liver and kidney, choline can provide lable methyl groups for the regeneration of methionine from homocysteine by betaine-homocysteine methyltransferase (BHMT). This alternative pathway is an important means of maintaining methylation capacity under conditions of folate, vitamin B-12, and methionine deficiency (18). Excess intracellular homocysteine can also be removed from the methylation pathway by conversion to cystathionine in the transsulfuration pathway or through export into circulation (17).

From these pathways, folate deficiency can generally be predicted to limit methionine synthesis and thereby SAM availability and to cause SAH to accumulate in tissues and homocysteine to accumulate in blood (hyperhomocysteinemia). At high concentrations, homocysteine might be directly toxic to cerebral blood vessels, but it is unclear whether mild elevations are similarly harmful. At the same time, rate-limiting concentrations of SAM together with feedback inhibition of some methyltransferase enzymes by elevated SAH concentrations would be expected to deplete the methylated products of such reactions. Nevertheless, these predictions do not always hold true, as the specific manifestations of folate deficiency differ by tissue (i.e. liver vs. brain), severity, and duration of the deficiency (19,20) and they can be modified by other metabolic factors, such as the availability of methionine and choline (21).

This complexity confounds the simple interpretation of epidemiological associations between cognitive impairments with folate, homocysteine, and other closely related metabolites and has impeded progress in clarifying the mechanisms that actually account for the epidemiological associations, whatever their theoretical plausibility (4,22,23).

Recent studies that have combined folate deficiency with other metabolic perturbations to expose genetic and pharmacological models of neurodegenerative disease to hyperhomocysteinemia have found that such treatments can exacerbate neurodegenerative or cognitive outcomes in models with preexisting neurological insults (24–26). However, such studies do not tell us whether the exacerbation of brain dysfunction is due to folate deficiency, hyperhomocysteinemia, or other factors (4,27). Earlier studies that specifically examined the effect of folate deficiency in rodents showed inconsistent effects on methylated derivatives of biogenic amine and cholinergic neurotransmitters (28–31). Other findings in folate-deficient rodents include ultrastructural abnormalities in rat brain capillaries (32) and slowed neurogenesis in mouse brain (33). Although folate-dependent changes in all these outcomes could ultimately lead to cognitive dysfunction, none of these studies report on the association of the neurochemical or structural impairments with cognitive outcomes.

In this study, we examined cognitive function in rats fed folate-deficient diets with and without supplemental methionine and determined the extent to which cognition in these rats corresponded to diet-induced changes in indicators of methylation activity: circulating homocysteine, liver and brain SAM and SAH, and brain membrane phosphatidylcholine and phosphatidylethanolamine.
from a total of 30–31 rats per group that were raised in 5 repeated cohorts (no. of rats allocated to each specific outcome measure are given in Tables 1–3).

**Cognitive and psychomotor testing.** Spatial learning and memory were evaluated by the Morris water maze and psychomotor function was evaluated by the accelerating Rotarod and wire suspension tests (36) during the 10th and last week of the experiment. Using these tests, we have shown that in mice, combined folate, vitamin B-12, and vitamin B-6 deficiency causes specific cognitive deficits on the Morris water maze but not in psychomotor performance (37).

**Morris water maze.** The Morris water maze is a well-validated and highly sensitive test of rodent cognitive function and is particularly sensitive to hippocampal dysfunction. The maze requires a rat to use spatial learning to find a hidden platform submerged below the surface of the water in a circular pool filled with water. The rat must use distal cues placed outside of the maze to effectively locate and remember the location of the escape platform from previous trials. Accurate navigation is rewarded with escape from the water onto the hidden platform. In this study, we used a 4-d-testing protocol as previously described (36). Briefly, rats underwent 3 d of training in the maze of 6 trials each day, followed by a fourth and final day of testing in which the position of the escape platform was changed, thereby requiring the rat to retain the learned escape strategy and to quickly learn the new escape position. Trial 6 on d 2–4 was a probe trial in which the platform was removed and the rat was allowed to swim for 60 s to assess spatial strategies before the trial was stopped. On d 4, following the probe trial, rats were tested on their ability to escape to a visible platform raised above the water’s surface to determine if differences in performance were not the result of differences in visual acuity. Performances were videotaped and analyzed with image tracking software (HVS Image). Performance variables including escape latency for the training trials, latency to the escape position for the probe trials, swim speed, and swim path length were automatically generated by the software.

**Wire suspension.** The wire suspension assay measured muscle strength and the prehnies reflex, an animal’s ability to grasp a taut horizontal wire with its forepaws and to remain suspended. Rats were held gently by the tail and the forepaws were placed on a suspended wire 2 mm in diameter and 62 cm above a cushioned surface. The latency to let go was measured using a stopwatch, with shorter latency to drop indicating reduced strength and/or reflex ability. If a rat did not let go of the wire within 60 s, it was removed from the wire and a latency of 60 s was assigned to that measurement. Each animal was used only once in the wire suspension assay.

**Rotarod.** The Rotarod assay measures motor coordination and balance. Rats were placed on a rotating 7-cm-diameter cylinder (Ugo Basile).

**Table 1** The effect of diet on Morris water maze and psychomotor performance.

<table>
<thead>
<tr>
<th>Morris water maze performance (d 4 reversal task)</th>
<th>C</th>
<th>FD</th>
<th>FDM</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>21</td>
<td>20</td>
<td>20</td>
<td>0.003</td>
</tr>
<tr>
<td>Mean escape latency, s</td>
<td>16.6 (7.3)a</td>
<td>24.2 (11.6)b</td>
<td>14.8 (7.8)b</td>
<td>0.003</td>
</tr>
<tr>
<td>Probe trial escape latency</td>
<td>5.9 (4.4)</td>
<td>9.1 (8.2)</td>
<td>5.6 (4.9)</td>
<td>0.127</td>
</tr>
<tr>
<td>Probe trial swim speed, m/s</td>
<td>0.24 (0.03)</td>
<td>0.24 (0.03)</td>
<td>0.24 (0.03)</td>
<td>0.839</td>
</tr>
<tr>
<td>Probe trial swim distance, m</td>
<td>14.5 (1.8)</td>
<td>14.3 (1.7)</td>
<td>14.6 (1.7)</td>
<td>0.840</td>
</tr>
<tr>
<td>Visible platform trial escape latency, s</td>
<td>10.1 (7.3)</td>
<td>10.3 (7.9)</td>
<td>11.9 (10.7)</td>
<td>0.761</td>
</tr>
</tbody>
</table>

| Psychomotor performance | Accelerating rotarod latency, s | 40.8 (29.9) | 32.1 (20.2) | 46.4 (37.8) | 0.312 |
| Wire suspension latency, s | 20.6 (10.9) | 28.1 (16.9) | 25.6 (18.1) | 0.308 |

**Table 2** The effect of diet on plasma folate, vitamin B12, vitamin B6 and tHcy.

<table>
<thead>
<tr>
<th></th>
<th>Diet</th>
<th>C</th>
<th>FD</th>
<th>FDM</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>10</td>
<td>11</td>
<td>10</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Folate, nmol/L</td>
<td>148 (24)a</td>
<td>7 (2)b</td>
<td>61 (2)b</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Vitamin B-12, pmol/L</td>
<td>414 (63)</td>
<td>324 (98)</td>
<td>410 (91)</td>
<td>0.050</td>
<td></td>
</tr>
<tr>
<td>Vitamin B-6, nmol/L</td>
<td>675 (136)</td>
<td>619 (212)</td>
<td>585 (153)</td>
<td>0.581</td>
<td></td>
</tr>
<tr>
<td>tHcy, µmol/L</td>
<td>4.2 (1.8)a</td>
<td>31.3 (8.3)b</td>
<td>31.2 (6.9)b</td>
<td>0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3** The effect of diet on brain and liver SAM, SAH and membrane lipids.

<table>
<thead>
<tr>
<th></th>
<th>Diet</th>
<th>C</th>
<th>FD</th>
<th>FDM</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver SAM, nmol/g</td>
<td>40.8 (29.9)</td>
<td>32.1 (20.2)</td>
<td>46.4 (37.8)</td>
<td>0.312</td>
<td></td>
</tr>
<tr>
<td>Wire suspension latency, s</td>
<td>20.6 (10.9)</td>
<td>28.1 (16.9)</td>
<td>25.6 (18.1)</td>
<td>0.308</td>
<td></td>
</tr>
</tbody>
</table>

1 Values are means ± SD. Means in a row with superscripts without a common letter differ, P < 0.05.

Each rat was placed on the rod at 2 rpm until it maintained its grip and orientation without assistance. The rod then accelerated steadily for 5 min (by 2 rpm every 30 s) until it reached 20 rpm. Latency to fall (maximum = 300 s) was recorded, with shorter latencies indicating impaired performance.

**Blood and tissue assays.** Rats were food-deprived overnight, decapitated, and trunk blood and tissues were rapidly harvested. EDTA plasma was separated within an hour of collection and frozen at −80°C for further analysis. Folate and vitamin B-12 were measured using the Quanaphase II radioassay kit (Bio-Rad Laboratories). Pyridoxal 5’-phosphate (vitamin B-6) was determined by the tyrosine decarboxylase apoenzyme methodology (38). tHcy was determined by HPLC (39).

Brains were rapidly harvested and snap-frozen in liquid nitrogen. Frozen whole brain tissue (including cerebrum, cerebellum, and medulla) was ground to a fine powder in liquid nitrogen. Tissue SAM and SAH levels were determined by liquid chromatography MS (40). Brain membranes were isolated by ultracentrifugation (41), followed by separation and quantification of membrane phospholipids (42). Briefly, phospholipids were separated by 2-dimensional TLC using a serum lipid mixture as a standard to identify individual phospholipids and which are quantified by their inorganic phosphorus (Pi) content, expressed as nmol Pi/mg protein (43).

**Data analysis.** Behavioral and biochemical data were analyzed using 1-way ANOVA with diet as a between-groups measure. Morris water maze data were analyzed using 3-way ANOVA (day × trial × diet) with day of testing and trial as repeated measures, diet as a between-groups measure, and with post-hoc Tukey’s honestly significant difference tests as appropriate. Descriptive statistics are expressed as means ± SD and α was set at 0.05 throughout.
Results

All rats gained weight after receiving the diets and had no morbidity. At the end of the study, the body weight of FD rats (225.5 ± 8.7 g) was ~3% greater than of FDM rats (217.8 ± 12.3 g) \((P < 0.05)\), but neither differed from the C group (220.4 ± 8.8 g). Brain wet weight was not affected by diet and was 1.71 ± 0.04 g for all rats combined.

Cognitive and psychomotor testing. Performance on the wire suspension task and the Rotarod task (did not vary as a function of diet (Table 1). However, in the Morris water maze, the performance of the folate-deficient rats was significantly impaired (Fig. 2). When escape latencies for all trials were compared, all rats acquired the task during the first 3 d of training \((P < 0.001)\). However, when comparing trials for each day, FD rats had a slower learning curve on d 2 and 3 of training and were slower to escape to the hidden platform compared with the other 2 groups by d 3 of training \((P < 0.05)\). Furthermore, FD rats were impaired in their ability to retain the escape strategy and relearn the new escape position when the escape platform was repositioned on the d 4 reversal trial \((P < 0.005)\). Methionine supplementation prevented the folate deficiency-induced impairment so that FDM rats performed at control levels.

The diets did not significantly affect probe trial performance. Nevertheless, folate deficiency nearly doubled \((P, d 4 = 0.127)\) the mean time required by the FD rats to reach the escape position, whereas FDM rats performed as well as controls (Table 1; Fig. 3A). During the training (d 2 and 3) and reversal probe trials (d 4), FD rats crossed the escape platform position slightly less often \((P, d 4 = 0.199)\) than the other groups (Fig. 3B); however, all groups spent significantly more time swimming in the correct escape quadrant than would be expected by chance (i.e. 25% of trial time).

The effects of diet on water maze performance could not be attributed to physical impairments given that diet: 1) did not affect swim speed or path length when the escape platform was removed from the pool on the probe trial; 2) did not affect escape latencies when the escape platform was raised above the surface of the pool in full view of the rats; and 3) did not affect
strength and psychomotor performance on the accelerating Rotarod and wire suspension tasks (Table 1).

**Blood chemistry.** Food-deprived plasma folate concentrations were <5% of control values for FD rats. Consistent with this finding, plasma tHcy in FD rats was more than 6-fold higher than in control. The FDM diet did not alter the severity of folate depletion or hyperhomocysteinemia induced by the FD diet (Table 2).

**Tissue SAM and SAH.** Liver metabolism was significantly affected by the experimental diets. Folate deficiency caused a significant ~60% decrease in food-deprived SAM concentrations and almost doubled liver SAH concentrations irrespective of dietary methionine. Conversely, dietary methionine did not change food-deprived liver SAM or SAH concentrations, regardless of folate status (Table 3).

In contrast to liver, brain SAM and SAH concentrations were resistant to the peripheral folate-induced metabolic perturbations. A minor but significant reduction of brain SAM concentrations was induced by folate deficiency, but the absolute mean concentrations were no greater than 1.2–1.5 μmol (8–10%) lower in FD and FDM rats than in C rats. Brain SAH concentrations were not affected by any diet and the SAM:SAH ratio tended to be lower in the FDM rats than in controls (P = 0.02; Table 3).

We also measured liver and brain SAM and SAH in tissues that were harvested from rats that were not food deprived before they were killed. Methionine supplementation of the FDM diet significantly elevated both fed SAM and SAH concentrations compared to both C and FD diets with normal methionine. However, brain SAM and SAH concentrations were almost the same in the food-deprived and fed states regardless of diet. Moreover, in the fed state, the SAM:SAH ratios in both liver and brain did not differ by diet group (data not shown).

**Brain membrane phospholipids.** While brain membrane phosphatidylcholine concentration in rats fed the FD diet (93.1 ± 17.0 nmol Pi/mg protein) was one-half that of C rats (187.8 ± 43.6 nmol Pi/mg protein), the supplemental methionine in the FDM diet maintained brain membrane phosphatidylcholine at the control level (191.8 ± 51.1 nmol Pi/mg protein). Regardless of whether the diets contained normal or high methionine, brain membrane phosphatidylethanolamine content was ~300% higher in rats fed folate-deficient diets than in controls.

These changes significantly affected membrane composition expressed as the ratio of brain membrane phosphatidylcholine to phosphatidylethanolamine. In C rats, brain membranes contained 3.5 times as much phosphatidylcholine than phosphatidylethanolamine (PC:PE = 3.5). In FD rats, this ratio was reversed such that membrane phosphatidylethanolamine was 43% higher than membrane phosphatidylcholine content (PC:PE = 0.7). High methionine only partially mitigated this abnormality, restoring membrane phosphatidylethanolamine content to the same level as that of control rats but retaining the high concentration of phosphatidylethanolamine. The PC:PE ratio under these conditions was 1.5 (Table 3).

**Discussion**

The present study shows that in rats, diet-induced folate deficiency perturbs not only SAM, SAH, and homocysteine metabolism but also depletes brain membrane phosphatidylcholine. This folate-dependent depletion of brain membrane phosphatidylcholine was prevented by supplementing the FD diet with l-methionine. We also show that folate deficiency impairs cognition as indicated by poorer performance on a sensitive test of spatial learning and memory. As with phosphatidylcholine, this folate-dependent cognitive impairment was prevented by supplementing the FD diet with l-methionine. The observed association of depleted brain membrane phosphatidylcholine with cognitive impairment in folate deficiency and their concurrent prevention by methionine suggests that abnormal membrane phospholipid composition may play an important role in folate-related cognitive dysfunction.

The impaired capacity of the folate-deficient rats to retain the task and escape from the maze by locating the escape platform when it was repositioned on d 4 was similar to that observed in apolipoprotein E-deficient mice (44) and wild-type mice (37), where 1-carbon metabolism was disrupted by a combined folate-vitamin B-12 and vitamin B-6 deficiency. The main effect of folate deficiency was to impair the rate of learning, particularly on the reversal task, whereas the capacity to utilize spatial strategies to find the platform was only weakly affected. This learning decrement is reminiscent of cholinergic impairment in rats with controlled cortical injury, where the damage initially manifests as slower learning and only months later becomes evident in impaired spatial performance on the probe trial (45). It is also similar to the learning deficit in aged rats that also have difficulty learning a new platform location during reversal training (46), although typically, aging also impairs spatial preference on the probe trial (47,48). The apparent dissociation of folate's effect on the rate of learning and spatial performance suggests that it affects specific aspects of cognitive function (49,50). Furthermore, the finding that dietary methionine mitigated the folate-induced impairment points to the importance of the dietary and metabolic balance of additional methyl donors, including methionine and possibly choline in determining the cognitive impact of poor folate status.

Biochemically, our findings are consistent with evidence of a close metabolic linkage of folate, choline, and methionine in 1-carbon transfer reactions and synthesis in vivo. Phosphatidylcholine can be synthesized from choline by the cytidylylcholine pathway or from the methylation of phosphatidylethanolamine. The latter is catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT) (51). The PEMT reaction is the only known pathway for the de novo synthesis of choline. It occurs extensively in liver but is also important in brain. In contrast, the cytidine (5’)-diphosphocholine pathway merely redistributes preexisting choline moieties between different phospholipid molecules (52). In rats, choline deficiency depletes not only liver choline, betaine, and phosphatidylcholine but also methionine, SAM, and folate, whereas folate deficiency has been shown to deplete choline and phosphocholine (53) and limit phosphatidylethanolamine methylation in liver, increasing its membrane concentration at the expense of phosphatidylcholine (54,55). However, these effects were not found in brain. Similarly, in humans, low folate intake significantly reduces plasma choline and phosphatidylcholine levels (56).

Functionally, abnormal membrane phospholipid composition can be predicted to adversely affect neurotransmission. Membrane phospholipid composition is an important modulator of cellular signal transduction (57). It influences receptor function through membrane-protein interactions and determines the availability of phospholipid degradation products that function as second messengers (51,58–60) and some of
these processes may be regulated by the PEMT-catalyzed synthesis of phosphatidylcholine (60,61). Finally, in cholinergic neurones, membrane phosphatidylcholine may serve as a choline reservoir to ensure its rapid availability for neurotransmitter synthesis (62). If the demand for choline exceeds supply, then cell membranes may be degraded to liberate choline (63). Thus, it is possible that in addition to the absolute membrane content of phosphatidylcholine, the observed shift in the ratio of phosphatidylcholine:phosphatidylethanolamine from a preponderance of phosphatidylcholine to a preponderance of phosphatidylethanolamine in cognitively impaired rats represents 2 functionally important membrane anomaly. Such changes are most likely to be evident in cholinergic structures, such as the nucleus basalis, or in brain regions with a high requirement for methylation, such as striatum. Identification of regional effects of folate deficiency on PEMT activity, membrane phospholipid composition, and acetylcholine content might help to test these predictions.

Interestingly, in postmortem brain tissue from Alzheimer’s disease patients, brain phosphatidylcholine content and PEMT activity in the frontal cortex have been found to be decreased compared to controls (52).

It is unlikely that homocysteine mediated the observed folate deficiency-induced cognitive impairment. If hyperhomocysteinemia were fully responsible for the folate-induced cognitive impairment, then cognition should not have improved upon methionine supplementation. Although it is possible that homocysteine could directly harm the brain or its vasculature under some conditions (26,32,37), the observed dissociation of hyperhomocysteinemia from cognitive impairment is important because it indicates that conditions exist where the association of hyperhomocysteinemia with cognitive impairment is insufficient as the causal mechanism.

We also examined the hypothesis that the association of poor folate status with cognitive dysfunction and decline is mediated by impaired brain methylation capacity, under the assumption that low folate limits the synthesis and availability of brain methionine and SAM. Our finding that supplemental methionine prevents cognitive impairment in the face of folate deficiency seems consistent with this hypothesis. However, it does not easily account for the resistance of brain SAM and SAH to perturbation by folate deficiency. Indeed, there was no significant difference in the SAM:SAH ratio (often referred to as the "methylation potential") did not differ in the brain of cognitively intact control rats and in cognitively impaired rats fed the folate-deficient diet with normal methionine. Conversely, the SAM:SAH ratio was significantly lower in the brain of cognitively intact rats fed folate-deficient, high-methionine diets. Nor can absolute brain SAM concentrations account for the cognitive impairment, because they were similarly decreased in rats fed the folate-deficient diets, irrespective of dietary methionine. Similarly, elevated brain SAH cannot account for the cognitive impairment, because SAH concentrations were not significantly elevated in the cognitively impaired rats. Moreover, the differences in SAM and SAH concentrations between control and folate-deficient, normal-methionine rats were very modest, amounting to an absolute difference of $-1.2 \mu$mol/L and $+0.3 \mu$mol/L, respectively (the equivalent of an 8% relative reduction in SAM and an 18% increase in SAH). Even if these differences were biologically meaningful, they do not explain the prevention of cognitive impairment by the addition of methionine to the folate-deficient diet, because the addition of methionine did nothing to improve SAM and SAH and in fact increased the differences. To the extent that global brain SAM and SAH concentrations reflect brain methylation capacity and activity, the modest diet induced changes in brain SAM and SAH concentrations do not indicate hypomethylation as a likely explanation for the observed cognitive impairment. However, global brain SAM and SAH concentrations may fail to capture regional differences in brain methylation potential and in the activity of specific methylation reactions.

If impaired methylation activity is nonetheless a mediator of folate deficiency-induced cognitive impairment, then it is likely that inhibition of specific methylation reactions will be more closely related than global methylation capacity to cognitive impairment. The activity of specific methyltransferase enzymes depends less on the SAM:SAH ratio than on the absolute concentrations and the enzyme’s Michaelis constant and inhibition constant (Km and Ki) for SAM and SAH, rendering some reactions more vulnerable than others to impaired methylation. Furthermore, SAM and SAH concentrations may reflect the steady state of the substrate and product of methylation reactions but may be less reliable indicators of the rate at which these reactions occur, or of the flux through the cycle. Thus, in theory, while brain SAM is maintained at a relatively stable homeostatic set point, an influx of methionine to brain could boost the availability of labile methyl groups.

In light of these considerations, it is not surprising that a neurologically important methylated compound such as phosphatidylcholine has a closer association with cognitive function than global SAM and SAH concentrations. However, as described above, dietary folate and methionine may determine brain phosphatidylcholine content, not only through brain PEMT activity, but also through the reciprocal relation of methionine and choline metabolism in liver. Our finding that folate deficiency resulted in increased membrane phosphatidylethanolamine content is consistent with the postulated inhibition of PEMT activity. Such inhibition would also explain the depletion of membrane phosphatidylcholine in folate deficiency with normal methionine. That the addition of methionine to the folate-deficient diet preserved brain membrane phosphatidylcholine has several possible explanations. One possibility is that methionine supplementation is sufficient to stimulate or restore PEMT activity that is otherwise limited by the secondary, folate-dependent methionine and SAM deficiency. Alternatively, enhanced availability of methionine might downregulate BHMT activity that would otherwise be required to compensate for inhibited folate-dependent methionine synthase activity. This in turn might protect choline, which would otherwise be consumed for methionine synthesis at the expense of phosphatidylcholine (64–66). If brain membrane phosphatidylcholine is preserved by methionine-dependent conservation of choline, then the fact that the BHMT reaction takes place primarily in liver but not in brain would point to a central contribution of liver phospholipid metabolism for brain function. This possibility is particularly intriguing given that the marked perturbation of liver SAM and SAH by folate deficiency was not ameliorated by methionine supplementation (Table 3).

In conclusion, the present study underscores the need for a far more detailed understanding of these metabolic and pathologic relationships than is currently available. Identifying the factors that enhance or mitigate folate- and homocysteine-related cognitive impairment will be crucial to effectively targeting these powerful, prevalent, and potentially modifiable risk factors for cognitive decline in older adults.

Acknowledgments
We thank Bina M. Albuquerque and Sherley Casseus for technical assistance with this study.
Literature Cited


21. Varela-Moreiras G, Ragel C, Pérez de Miguelsanz J. Choline deficiency and methotrexate treatment induces marked but reversible changes in hepatic folate concentrations, serum homocysteine and DNA methyl-